Author(s): Rodrigues, J ; Mineiro, A ; Reis, A ; Ventura, D ; Fernandez-Llimos, F ; Costa, F ; Gomes, J ; Silva, JM ; Lopes, P ; Robalo Cordeiro, C
Date: 2020
Persistent ID: http://hdl.handle.net/10400.17/3478
Origin: Repositório do Centro Hospitalar de Lisboa Central, EPE
Subject(s): HSM PNEU; Health Care Quality, Access, and Evaluation; Professional Practice; Standard of Care; alpha 1-Antitrypsin Deficiency/therapy
Alpha-1 antitrypsin deficiency is an autosomal co-dominant inherited disorder that results in decreased circulating levels of alpha-1 antitrypsin (also known as alpha-1 proteinase inhibitor) and predisposes affected individuals to early onset lung and liver disease. There is currently no cure for alpha-1 antitrypsin deficiency. However, appropriate treatment and a high standard of clinical care can prevent patients from being seriously affected and having to undergo major medical interventions, such as organ transplantation. Beyond managing the symptoms associated with alpha-1 antitrypsin deficiency, alpha-1 proteinase inhibitor therapy is the only treatment for the condition's underlying cause. Early diagnosis is important to ensure efficient therapeutic strategies and to minimize further deterioration of lung function. alpha-1 antitrypsin deficiency is under diagnosed globally, partly because the disease has no unique presenting symptoms. This document was prepared by a Portuguese multidisciplinary group and it aims to set out comprehensive principles of care for Alpha-1 antitrypsin deficiency. These include the importance of registries, the need for clinical research, the need for consistent recommendations (regarding diagnosis, treatment and monitoring), the role of reference centres, the requirement for sustained access to treatment, diagnostic and support services, and the role of patient organizations.
